Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus ZERVIATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus ZERVIATE.
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs ZERVIATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
ZERVIATE (cetirizine ophthalmic solution) contains cetirizine, a selective histamine H1 receptor antagonist. It inhibits histamine-induced vasodilation and increased vascular permeability, leading to reduction of ocular itching associated with allergic conjunctivitis.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
1 drop in each affected eye twice daily (approximately 8 hours apart).
None Documented
None Documented
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Terminal elimination half-life is approximately 3 hours; clinical context: supports twice-daily topical ocular dosing for allergic conjunctivitis.
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Primarily renal excretion of unchanged drug (approximately 70%) and metabolites; biliary/fecal elimination accounts for less than 20%.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine